Actively Recruiting

Age: 18Years +
All Genders
NCT06373913

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Led by Kolding Sygehus · Updated on 2025-09-09

75

Participants Needed

1

Research Sites

269 weeks

Total Duration

On this page

Sponsors

K

Kolding Sygehus

Lead Sponsor

O

Odense University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality. The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses: 1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.

CONDITIONS

Official Title

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years old
  • Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.
Not Eligible

You will not qualify if you...

  • Refusal to give informed consent
  • Treatment with PCSK9 inhibitors
  • Any acute or chronic condition that would limit the ability of the patient to participate in the study
  • Control group: proteinuria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kolding Sygehus, Lillebælt Hospital

Kolding, Denmark, 6000

Actively Recruiting

Loading map...

Research Team

R

Rikke Z Langkilde, MD, phd

CONTACT

A

Anne D Thuesen, MD, phd

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here